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Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19
patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2
which is consistent across patients. Clonal expansion of the B cell population is also
observed and may be the result of memory bystander effects. There was a
strong convergent sequence signature across patients, and we identified 1,254
clonotypes convergent between at least four of the COVID-19 patients, but not present
in healthy controls or individuals following seasonal influenza vaccination. A subset of the
convergent clonotypes were homologous to known SARS and SARS-CoV-2 spike
protein neutralizing antibodies. Convergence was also demonstrated across wide
geographies by comparison of data sets between patients from UK, USA, and China,
further validating the disease association and consistency of the stereotypical immune
response even at the sequence level. These convergent clonotypes provide a resource to
identify potential therapeutic and prophylactic antibodies and demonstrate the potential of
BCR profiling as a tool to help understand patient responses.
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Since the report of the first patients in December 2019 (1, 2), the unprecedented global scale of the
COVID-19 pandemic has become apparent. The infectious agent, the SARS-CoV-2 betacoronavirus
(3), causes mild symptoms in most cases but can cause severe respiratory diseases such as acute
respiratory distress syndrome in some individuals. Risk factors for severe disease include age, male
gender, and underlying co-morbidities (4).org December 2020 | Volume 11 | Article 6051701
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infection is critical to support the development of therapies.
Recombinant monoclonal antibodies derived from analyses of B
cell receptor (BCR) repertoires in infected patients or the
immunization of animals have been shown to be effective
against several infectious diseases including Ebola virus (5),
rabies (6), and respiratory syncytial virus disease (7). Such
therapeutic antibodies have the potential to protect susceptible
populations as well as to treat severe established infections.
While many vaccine approaches are underway in response to
the SARS-CoV-2 outbreak, many of these compositions include
as immunogens either whole, attenuated virus or whole spike (S)
protein—a viral membrane glycoprotein which mediates cell
uptake by binding to host angiotensin-converting enzyme 2
(ACE2). The antibody response to such vaccines will be
polyclonal in nature and will likely include both neutralizing
and non-neutralizing antibodies. It is hoped that the neutralizing
component will be sufficient to provide long-term SARS-CoV-2
immunity following vaccination, although other potential
confounders may exist, such as raising antibodies which
mediate antibody-dependent enhancement (ADE) of viral
entry (8–10). While ADE is not proven for SARS-CoV-2, prior
studies of SARS-CoV-1 in non-human primates showed that,
while some S protein antibodies from human SARS-CoV-1
patients were protective, others enhanced the infection via
ADE (11). An alternative could be to support passive
immunity to SARS-CoV-2, by administering one, or a small
cocktail of, well-characterized, neutralizing antibodies.
Patients recovering from COVID-19 have already been
screened to identify neutralizing antibodies, following analysis of
relatively small numbers (100–500) of antibody sequences (12–
14). A more extensive BCR repertoire analysis was performed on
six patients in Stanford, USA with signs and symptoms of
COVID-19 who also tested positive for SARS-CoV-2 RNA (15).
Although no information was provided on the patient outcomes in
that study, the analysis demonstrated preferential expression of a
subset of immunoglobulin heavy chain (IGH) V gene segments
with relatively little somatic hypermutation and showed evidence
of convergent antibodies between patients.
To drive a deeper understanding of the nature of humoral
immunity to SARS-CoV-2 infection and to identify potential
therapeutic antibodies to SARS-CoV-2, we have evaluated the
BCR heavy chain repertoire from 31 individuals at various stages
of their immune response. We show that there are stereotypic
responses to SARS-CoV-2 infection, that infection stimulates
both naïve and memory B cell responses, that sequence
convergence can be used to identify putative SARS-CoV-2
specific antibodies, and that sequence convergence can be
identified between different SARS-CoV-2 studies in different
locations and using different sample types.METHODS
Clinical Information Gathering
Peripheral blood was obtained from patients admitted with acute
COVID-19 pneumonia to medical wards at Barts Health NHSFrontiers in Immunology | www.frontiersin.org 2Trust, London, UK, after informed consent by the direct care team
(NHS HRA RES Ethics 19/SC/0361). Venous blood was collected in
20-ml EDTA Vacutainers (BD). Patient demographics and clinical
information relevant to their admission were collected by members
of the direct care team, including duration of symptoms prior to
blood sample collection. Current severity was mapped to the WHO
Ordinal Scale of Severity. Whether patients at time of sample
collection were clinically Improving, Stable or Deteriorating was
subjectively determined by the direct clinical team prior to any
sample analysis. This determination was primarily made on the
basis of whether requirement for supplemental oxygen was
increasing, stable, or decreasing comparing current day to
previous 3 days. Lymphocyte counts were determined using a
standard clinical cytometer.
Sample Collection and Initial Processing
Blood samples were processed within 1 h of collection in order to
limit RNA degradation. Blood was first centrifuged at 150 xg for
15 min at room temperature to separate plasma. The cell pellet
was then resuspended with phosphate-buffered saline (PBS
without calcium and magnesium, Sigma) to 20 ml, layered
onto 15-ml Ficoll-Paque Plus (GE Healthcare) and then
centrifuged at 400 xg for 30 min at room temperature without
brake. Mononuclear cells (PBMCs) were extracted from the buffy
coat and washed twice with PBS at 300 xg for 8 min. PBMCs were
counted with Trypan blue (Sigma) and viability of >96% was
observed. PBMCs (5 × 106) were immediately resuspended in
RLT buffer to stabilize the RNA (Qiagen) and incubated at room
temperature for 10 min prior to storage at –80°C. Consecutive
donor samples with sufficient RLT samples progressed to RNA
preparation and BCR preparation and are included in
this manuscript.
Metastatic breast cancer biopsy samples were collected and
RNA extracted as part of a previously reported cohort (16).
RNA Prep and BCR Sequencing
Total RNA from 5 × 106 PBMCs was isolated using RNeasy kits
(Qiagen). First-strand cDNA was generated from total RNA
using SuperScript RT IV (Invitrogen) and IgA and IgG isotype
specific primers (17) including UMIs at 50°C for 45 min
(inactivation at 80°C for 10 min).
The resulting cDNA was used as template for High Fidelity
PCR amplification (KAPA, Roche) using a set of 6 FR1-specific
forward primers (17) including sample-specific barcode
sequences (6 bp) and a reverse primer specific to the RT
primer (initial denaturation at 95°C for 3 min, 25 cycles at
98°C for 20 s, 60°C for 30 s, 72°C for 1 min and final extension at
72°C for 7 min). The amount of BCR heavy chain amplicons
(~450 bp) was quantified by TapeStation (Beckman Coulter) and
gel-purified.
Dual-indexed sequencing adapters (KAPA) were ligated onto
500-ng amplicons per patient using the HyperPrep library
construction kit (KAPA) and the adapter-ligated libraries were
finally PCR-amplified for 3 cycles (98°C for 15 s, 60°C for 30 s,
72°C for 30s, final extension at 72°C for 1 min). Pools of 10, 9,
and 12 libraries were sequenced across three runs on an Illumina
MiSeq using 2 × 300 bp chemistry.December 2020 | Volume 11 | Article 605170
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The Immcantation framework (docker container v3.0.0) was
used for sequence processing (18, 19). Briefly, paired-end reads
were joined based on a minimum overlap of 20 nt, and a max
error of 0.2, and reads with a mean phred score below 20 were
removed. Primer regions, including UMIs and sample barcodes,
were then identified within each read, and trimmed. Together,
the sample barcode, UMI, and constant region primer were used
to assign molecular groupings for each read. Within each
grouping, usearch (20) was used to subdivide the grouping,
with a cutoff of 80% nucleotide identity, to account for
randomly overlapping UMIs. Each of the resulting groupings is
assumed to represent reads arising from a single RNA. Reads
within each grouping were then aligned, and a consensus
sequence determined. Finally, duplicate reads were collapsed
into a single processed sequence for analysis. Collapsing
duplicate reads ensures that each processed sequence
represents a sequence from a single B cell and our analysis is
not confounded by expression level.
For each processed sequence, IgBlast (21) was used to
determine V, D and J gene segments, and locations of the
complementarity determining regions (CDRs) and framework
regions (FWRs). Isotype was determined based on comparison to
germline constant region sequences. Sequences annotated as
unproductive by IgBlast were removed. The number of
mutations within each sequence was determined using the
shazam R package (19).
Public BCR Sequence Data Processing
The healthy control BCR sequence dataset used here has been
described previously (22). It was prepared using the same primer set
that was used in the current study, so comparisons should not suffer
from protocol-specific biases. Only samples from participants aged
10 years or older, and from peripheral blood were used. This
resulted in samples from 40 different participants, with a mean
age of 28 (range: 11–51). Furthermore, only class-switched
sequences were considered.
The influenza vaccine BCR sequence dataset used here was a
combination of data from two different studies, and amounted to
samples from 6 different participants in total (23, 24). All
participants were administered a seasonal influenza vaccine,
and peripheral blood was taken for BCR sequencing 6–9 days
following vaccination. The processed data from these studies was
obtained directly from the Observed Antibody Space database,
and only the class-switched sequences were considered (25).
The publicly available BCR sequence dataset from six
COVID-19 patients in Stanford, USA was also obtained
directly from the Observed Antibody Space database. To
circumvent the disparity in collapsed dataset sizes between
pairs of replicates, we selected the replicate with the highest
number of sequences for downstream analysis.
Clonotyping
BCR sequences were clustered to identify those arising from
presumably clonally related B cells; a process termed clonotyping.Frontiers in Immunology | www.frontiersin.org 3Sequences from the 31 COVID-19 patients, the 7 metastatic cancer
patients, the 6 influenza vaccine participants, and the 40 healthy
controls were clustered together to also identify convergent clusters
between samples. Clustering was performed using a previously
described algorithm (26). Clustering required identical V and J
gene segment usage, identical CDRH3 length, and allowed 1 AA
mismatch for every 10 AAs within the CDRH3. Cluster centers were
defined as the most common sequence within the cluster. Lineages
were reconstructed from clusters using the alakazam R
package (27).
Bronchoalveolar Lavage RNAseq Data
Processing
The bronchoalveolar lavage data comes from a previously
published study of SARS-CoV-2 infection (28), with data
available under the PRJNA605983 BioProject on NCBI.
MIXCR v3.0.3 was used, with default settings, to extract reads
mapping to antibody genes from the total RNASeq data (29).
Convergent Clonotype Matching to Public
Data
The public COVID-19 BCR sequence dataset (15), the output
from the SARS-CoV-2 RNAseq data processing (28), and
sequences from CoV-AbDab (30) were scanned for matches to
our 1,254 convergent clonotype cluster centers. For comparison
to the COVID-19 BCR sequence dataset and the RNAseq dataset,
matching was performed using the same threshold that was used
for clonotyping – requiring identical V and J genes, the same
length CDRH3, and within 1 AA mismatch per 10 CDRH3 AAs
to the convergent clonotype cluster center. For matching to the
CoV-AbDab, a more lenient threshold was used. Sequences from
CoV-AbDab were clustered alongside the representative CDRH3
sequence from each of our 1,254 convergent clones using the cd-
hit-2d script from the CD-HIT package (31), at an 80% sequence
identity threshold. Clustered CDRH3s were not required to have
the same length, however the shorter CDRH3 was required to be
at least 90% of the length of the longer CDRH3. Cluster centers
containing at least one CoV-AbDab CDRH3 and one convergent
clonotype CDRH3 were further investigated.
Statistical Analysis and Graphing
Statistical analysis and plotting were performed using R (32).
Plotting was performed using ggplot2 (33). Specific statistical
tests used are detailed in the figure legends. Correlations of
IGHV4-34 autoreactive motifs was performed by MANOVA
in R.RESULTS
COVID-19 Disease Samples
Blood samples were collected from thirty-one patients admitted
to hospital with acute COVID-19 pneumonia. The mean age of
patients was 56.2 (SD 17.7) years and 20 (65%) were male
(Supplementary Table 1). All patients had a clinical historyDecember 2020 | Volume 11 | Article 605170
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Twenty-eight patients had a confirmatory positive PCR test for
SARS-CoV-2. The patients experienced an average of 16 days
(range 4–55) of symptoms prior to the day on which the blood
sample was collected. Twelve of the patients were still requiring
hospital care but not oxygen therapy on day of sample collection
(WHO Ordinal Scale Score 3), while 13 were hospitalized
requiring oxygen by conventional mask or nasal prongs (WHO
Ordinal Scale Score 4) and six were hospitalized with severe
COVID-19 pneumonia requiring high-flow nasal oxygen or
continuous positive airway pressure by mask (WHO Ordinal
Scale Score 5). On the day of sample collection, the direct clinical
care team considered two patients to be deteriorating, ten
improving and the remaining nineteen were clinically stable.
It has previously been observed that lymphopenia is seen in
severe COVID-19 patients (34). Our results recapitulate these
findings, showing a correlation between lymphocyte count and
clinical status (Supplementary Figure 1). As COVID-19
lymphopenia is caused by a reduction in T cell rather than B
cell counts, we do not expect the different lymphocyte counts
from our patients to impact the BCR sequencing results.Frontiers in Immunology | www.frontiersin.org 4SARS-CoV-2 Infection Results in a
Stereotypic B Cell Response
IGHA and IGHG BCR sequencing yielded on average 154,717
unique sequences, and 24,043 clonotypes per sample
(Supplementary Table 1). To characterize the B cell response in
COVID-19, we compared this BCR repertoire data to BCR
repertoire data from healthy controls obtained in a separate study
(Supplementary Table 2), but amplified using the same primer set
(22). Comparing IGHV gene segment usage revealed a significantly
different IGHV gene usage in COVID-19 patients compared to the
healthy controls, most notably with increases in the usage of
IGHV2-70 (3.6× IGHA, 3.9× IGHG increase), IGHV3-30 (1.7×
IGHA, 1.4× IGHG increase), IGHV5-51 (3.2× IGHA, 3.2× IGHG
increase), and IGHV4-34 (1.2× IGHA, 2.2× IGHG increase) in the
COVID-19 patients (Figure 1A).
We further investigated the IGHV4-34 difference, as IGHV4-34
has been shown to produce self-reactive antibodies (35). The
IGHV4-34 germline sequence contains two sequence motifs (an
“AVY” hydrophobic patch in the FWR1, and an “NHS”
glycosylation sequon in the CDR2) that are not found in other
IGHV gene segments and are thought to drive the self-reactivity. WeA
B C
FIGURE 1 | B cell responses to SARS-COV-2 infection. (A) IGHV gene segment usage distribution per isotype. (B) Isotype subclass distribution between IGHA and IGHG
subclasses, and (C) mean BCR CDRH3 lengths from COVID-19 patients compared to healthy controls. For (A–C), bars show mean values +/− standard error of the mean.
Comparisons performed using t-tests, with adjusted p values using Bonferroni correction for multiple comparisons; * p < 0.05, ** p < 0.005, *** p < 0.0005.December 2020 | Volume 11 | Article 605170
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AVY & NHS sequence motifs is increased in improving COVID-19
patients compared to stable or deteriorating COVID-19 patients,
specifically in the IGHG1 isotype subclass (p-value = 0.013;
Supplementary Figure 2).
Comparing isotype subclasses showed a significant increase in
the relative usage of IGHG1 in COVID-19 patients (Figure 1B)—
this is the first isotype subclass that is switched to upon activation
of IGHM (36). There was also an increase in the mean CDRH3
length of the BCRs in the COVID-19 patients, that was most
pronounced in the IGHA1, IGHA2, and IGHG1 isotype subclasses
(Figure 1C).
SARS-CoV-2 Infection Stimulates Both
Naïve and Memory Responses
To further investigate the COVID-19-specific B cell response, we
analyzed the characteristics of the BCR sequences that are
consistent with recent B cell activation—somatic hypermutation
and clonal expansion. In healthy controls, for class-switched
sequences, there is a clear unimodal distribution of sequences
with different numbers of mutations, and a mean mutation count
across IGHA and IGHG isotypes of 17.6 (Figure 2A). In the
COVID-19 samples, the meanmutation count was 14.8, and there
was a bimodal distribution with a separate peak of sequences with
no mutations. This bimodal distribution was most pronounced in
the IGHG1, IGHG3, and IGHA1 isotype subclasses, corresponding
to the increased isotype usages. Such a distribution is consistent
with an expansion of recently class-switched B cells that have yet to
undergo somatic hypermutation. There was considerable variationFrontiers in Immunology | www.frontiersin.org 5between participants in the proportion of unmutated sequences
(Supplementary Figure 3), which had no significant correlation
with the number of days since symptom onset (R = −0.098, p =
0.61), but was lower in the deteriorating compared to improving
patients (Figure 2B).
To investigate the clonal expansion in these antigen experienced
BCR repertoires in more detail, the Shannon diversity index of each
repertoire was calculated (while accounting for differences in read
depth through subsampling). Lower diversity is indicative of a small
number of dominant clonal expansions, while higher diversity is
indicative or a larger number of smaller clonal expansions. The
class-switched BCR repertoires of the COVID-19 patients were
significantly less diverse than the BCR repertoires of the healthy
controls due to the presence of large clonal expansions (Figures 2C,
D), but there was no relationship between disease state and BCR
repertoire diversity (Figure 2E). Calculating the mean mutation
count of the clonal expansions showed that the largest ones were all
highly mutated; the mean mutation of the ten largest clonal
expansions in each COVID-19 patient repertoire was 18.4. Taken
together, these observations suggest the response to COVID-19
consists of both recently activated B cells with low levels of mutation,
and historic memory B cells that have high levels of mutation, and
form particularly large clonal expansions.
Sequence Convergence Can Be Used to
Identify Putative SARS-CoV-2 Specific
Antibodies
Given the skewing of the B cell response in the COVID-19
patients to specific IGHV genes, we next investigated whetherA B
D EC
FIGURE 2 | Response characteristics of SARS-CoV-2 infection. (A) Distribution of sequences with different numbers of mutations from germline. (B) Relationship
between the proportion of the repertoire comprised by unmutated sequences, and the disease state (C) Individual sequences were clustered together into related
groups to identify clonal expansions (clonotypes). Diversity of all clonotypes in the repertoire calculated using the Shannon diversity index. To normalize for different
sequence numbers for each sample, a random subsample of 1,000 sequences was taken. (D) Network graphs of a representative repertoire from a single COVID-19
patient, and a single HC sample giving a graphical representation of the diversity. Each point represents one of the subsampled sequences, and sequences within
the same clonotype are linked together. (E) Relationship between repertoire diversity and disease state.December 2020 | Volume 11 | Article 605170
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between different participants. Such convergent BCR signatures
have been observed in response to other infectious diseases (37)
and may be used to identify disease-specific antibody sequences.
Of the 714,107 total clonotypes across all the COVID-19
patients, 17,658 (2.5%) were shared between at least two of the
participants (Figure 3A). Sample-to-sample contamination
within sequencing batches can erroneously be interpreted as
convergence, so we used a dual sample barcoding method, and
strict laboratory procedures to minimize this. Although an
element of contamination can never entirely be ruled out, we
found no batch effects between the three sequencing runs we
conducted (Supplementary Figure 4). As convergence could
also occur by chance or be due to an unrelated memory response
from commonly encountered pathogens, additional datasets
were incorporated into the convergence analysis. The healthy
control dataset was used to identify BCR sequences that may be
shared by chance or come from commonly encountered
pathogens. In addition, a BCR sequence dataset of six
individuals who had received an influenza vaccination 6–9
days prior to sampling, was used to further identify BCR
sequences that could arise during general respiratory tract
infection (23, 24).Frontiers in Immunology | www.frontiersin.org 6Of the 17,658 convergent clonotypes, 2,530 (14.3%) were also
present in at least one of the 40 healthy control samples, 1,400
(7.9%) were also present in at least one of the 6 influenza
samples, and 869 (4.9%) were also present in at least one of
the healthy controls and one of the influenza samples. As
expected, of the convergent clonotypes that were also present
in the healthy control or influenza samples, the mean mutation
count was significantly greater (Figure 3B), and the mean
CDRH3 length significantly shorter (Figure 3C) than the
convergent clonotypes that were unique to the COVID-
19 patients.
To identify a set of potentially SARS-CoV-2-specific antibody
sequences with high confidence, we first selected convergent
clonotypes that were shared between at least four of the COVID-
19 patients, but not seen in the healthy controls. This revealed 1,337
total clonotypes. For comparison, the same analysis was also
conducted on the influenza sample dataset but using a more
lenient threshold of sharing between at least two samples in order
to identify a similar total number of 1,180 total clonotypes. Finally,
as a technical control to determine whether the convergent
signature could represent laboratory contamination, the same
analysis was performed on an unrelated set of six metastatic




FIGURE 3 | Convergent BCR sequence signature within individuals infected with SARS-CoV-2. (A) Data from all patients and healthy controls were clustered
together to identify convergent clonotypes. Shown is the number of clonotypes shared by different numbers of participants, grouped by whether the clonotypes are
also present in the healthy control dataset. Of the convergent clonotypes, (B) the mean mutation count, and (C) the CDRH3 AA sequence length was compared
between those that were convergent only within the SARS-CoV-2 patients, and those that were also convergent with the healthy control dataset. (D) Heatmap of the
1,254 convergent COVID-19-associated clonotypes (observed between 4 or more COVID-19 participants) with the 1,180 convergent clonotypes from six influenza
vaccination (FLU) samples, and 351 convergent clonotypes from six metastatic breast cancer (BC) patient biopsy samples, demonstrating that the convergent
signatures are unique to each cohort.December 2020 | Volume 11 | Article 605170
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each of the COVID-19, influenza and metastatic cancer cohorts
were highly specific to each sample cohort (Figure 3D). Removing
the small amount of overlap that the 1,337 COVID-19 convergent
clonotypes had with the influenza and metastatic cancer samples
resulted in a final signature of 1,254 convergent clonotypes.
The 1,254 COVID-19 convergent clonotypes had low
mutation levels, with a mean mutation count of 2.3, and only
115 clonotypes with a mean mutation greater than 5. The
sequences within the convergent clonotypes were primarily of
the IGHG1 (71%) and IGHA1 (15%) subclasses (Supplementary
Figure 5A). The convergent clonotypes used a diversity of IGHV
gene segments, with IGHV3-30, IGHV3-30-3 and IGHV3-33 as
the most highly represented (Supplementary Figure 5B). This
IGHV gene usage distribution differs between that of the total
repertoire, and IGHV3-30 is also the most highly used IGHV
gene in the CoV-AbDab (30). The proportion of the repertoire
comprised by each of these convergent clonotypes was also
calculated for each patient sample. This proportion
significantly correlated with decreased disease severity for one
of the convergent clonotypes (IGHV3-30, CARGPGDSIDYW,
IGHJ4) even after Bonferroni correction for multiple testing
(p = 0.0052).
BCR Clonotype Sequence Convergence
Signatures are Shared Between Different
COVID-19 Studies in Different Locations
and From Different Anatomical Sites
To further explore whether the convergent clonotypes observed
in our study were indeed disease specific, and to determine
whether such convergence was common across studies and
geographic regions, we compared these 1,254 convergent
clonotypes to public B cell datasets. In addition, to ensure any
matches to public datasets were not due to chance, we also
selected at random 1,254 clonotypes from the healthy control set
and performed the same comparison in parallel.
First, we compared our data to RNAseq data of
bronchoalveolar lavage fluid obtained from five of the first
infected patients in Wuhan, China (28). These samples were
obtained for the purpose of metagenomic analyses to identify the
aetiological agent of the novel coronavirus but were re-analyzed
to determine whether we could extract any transcripts from
BCRs. From the 10,038,758 total reads, we were able to identify
16 unique CDR3 AA sequences (Supplementary Table 2). Of
these, one had an exact AA match to a CDR3 sequence in our
data (CTTDLHDYGDSDYW) and shared the same V gene
segment (IGHV3-15), and J gene segment (IGHJ4) usage. The
clonotype that the sequence belonged to contained 796 total
sequences and was convergent between 10 of our 31 COVID-19
patients. The clonotype was highly diverse, and the sequences
had evidence of low mutation from germline, with a mean
mutation count over all sequences of 5.3 (Supplementary
Figure 6). None of the 16 CDR3 sequences from the RNAseq
data matched to any of the CDR3 sequences in the 1,254 healthy
control clonotypes, or indeed from any of the clonotypes in the
entire dataset of 40 healthy control samples, indicating that theFrontiers in Immunology | www.frontiersin.org 7observed matching in the COVID-19 patients is unlikely just due
to chance alone.
Next, we compared our 1,254 convergent clonotypes to CoV-
AbDab – the Coronavirus Antibody Database (accessed 5th
August 2020) (30). At the time of access, this database
contained 1,396 redundant and 1,151 non-redundant CDRH3
sequences from published and patented antibodies proven to
bind coronaviruses including SARS-CoV-1 and SARS-CoV-2.
We found 39 of our 1,254 convergent clonotypes to have high
CDRH3 homology to the antibodies in CoV-AbDab (Table 1
and Supplementary Table 4). In contrast, only one of the 1,254
healthy control clonotypes had high CDR3 homology to an
antibody in CoV-AbDab. Of the 39 convergent clonotype
matches, 10 also shared the same IGHV and IGHJ gene
segment usage and would be classed as belonging to the same
clonotype (Table 1); the healthy control clonotype match did not
share the same IGHV or IGHJ gene segment usage.
Finally, we compared our data to a publicly available BCR
deep sequencing dataset from six COVID-19 patients from
Stanford, USA. Four hundred sixty-three of our 1,254
convergent clonotypes matched (using the same definition we
used for clonotyping within our dataset) sequences in this dataset
showing the high level of convergence between studies (Figure
4A and Supplementary Table 5). The average number of
clonotype matches to the Stanford COVID-19 patient
repertoires was 103, but this varied considerably between
patients and timepoints. Two of the six patients were
seronegative at the day of sampling (7451 and 7453), and these
two patients had the fewest clonotype matches (8 and 31,
respectively). Patient 7453 had an additional sample taken two
days later (following seroconversion), and at this point had a
large increase in the number of clonotype matches to 201. There
was one of the 1,254 convergent clonotypes that was found
across all six of the Stanford patients, and 2 clonotypes that were
found in all five samples from seroconverted patients, but not
found in the seronegative patients. In contrast, only 19 of the
1,254 healthy control clonotypes matched to sequences in the
Stanford dataset (Figure 4B).DISCUSSION
We have used deep sequencing of the BCR heavy chain
repertoire to evaluate the B cell responses of 31 individuals
with COVID-19. In agreement with previous studies, there was
a skewing of the repertoire in the response to SARS-CoV-2
infection, with an increased use of certain V genes, an increase in
the proportion of antibodies with longer CDRH3s, and an altered
isotype subclass distribution (15). The significantly increased
usage of IGHA1 observed in the COVID-19 patients is in line
with mucosal responses, where the longer hinge in IGHA1
compared to IGHA2 may offer advantages in antigen
recognition by allowing higher avidity bivalent interactions
with distantly spaced antigens (42).
As anticipated, given the novel nature of the virus, SARS-
CoV-2 infection largely stimulated a characteristically naïve-likeDecember 2020 | Volume 11 | Article 605170
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cells. There was an increased prevalence of unmutated, but class-
switched BCR sequences, an increase in the diversity of BCRs
present in the class-switched B cell compartment, and an
increase in the usage of isotype subclasses that are associated
with recent viral immunity. It is interesting that the levels of
mutation were so low given that the time point at which we
sampled these patients is on average 16 days since symptom
onset, and therefore even longer since initial infection. In
controlled vaccination studies, it has been seen that 10 days
post novel antigen challenge are sufficient to generate high levels
of mutation (43). Such expansion of unmutated but class-
switched BCR sequences has however also been seen in
humans following rotavirus (44) and dengue virus (45)
infection. In mice infected with vesicular stomatitis virus, it is
seen that there is an unmutated IgG response upon initial
infection which confers protection, but secondary challenge
results in increased mutation and a change in IGHV gene
segment usage (46). These observations are attributed to
natural, or autoreactive antibodies, which are produced rapidly
upon initial viral infection and recognize repetitive structures
such as viral capsids. The increased prevalence of autoreactive
IGHV4-34 sequences in improving COVID-19 patients
compared to stable or deteriorating COVID-19 patients furtherFrontiers in Immunology | www.frontiersin.org 8suggests a role for such natural or autoreactive antibodies in
resolving infection and lowering the risk of pathology.
In addition to the naïve response, analysis of the largest clonal
expansions in the SARS-CoV-2 patients, revealed them to be highly
mutated, indicating that they may have arisen from memory recall.
Such a secondary response to SARS-CoV-2 has been previously
observed (47) and may be due to recall of B cells activated in
response to previously circulating human coronaviruses, as recently
highlighted (48, 49).
We observed a potential relationship between the observed
repertoire characteristics and disease state. Improving patients
showed a tendency toward a higher proportion of unmutated
sequences compared to deteriorating patients, indicating that a
naïve B cell response may be more effective than a memory
recall response at clearing infection. Consistent with this
hypothesis, Wec et al. found that B cells derived from
memory recall generated low affinity, but SARS-CoV-1/2
cross-reactive antibodies, whereas B cells with the lowest
mutation counts generated higher affinity SARS-CoV-2
specific antibodies (47). There is a clear need to expand on
these findings by using larger sample cohorts and gathering
more clinical data to aid understanding of the differences
between individuals that respond with mild versus severe
disease and have different recovery patterns. Building uponTABLE 1 | Convergent COVID-19 clonotypes with high CDRH3 homology to antibodies in the CoV-AbDab, and which share the same IGHV and IGHJ gene usage and
CDRH3 length.
Name CDRH3 IGHV IGHJ Binds Neutralizes Reference
C154 AKQAGPYCSGGSCYSAPFDY 3-30 4 CoV-1, CoV-2 CoV-2 Robbiani et al. (14)
ALC_3983948 AKVSGPYCSGGSCYSFYFDY 3-30 4
COV2-2068 ARSYDILTGYRDAFDI 3-53 3 CoV-2 CoV-2 Zost et al. (38)
ALC_2318471 VRNYDILTGYSDAFDI 3-53 3
COV2-2007 AKVSATYYYYYYGMDV 3-30 6 CoV-1, CoV-2 Zost et al. (38)
CC12.17 AKSSGSYYYYYYGMDV 3-30 6 CoV-2 CoV-2 Rogers et al. (39)
ALC_2318830 AKVMTTYYYYYYGMDV 3-30 6
COVA2-14 ARVRYYDSSGYYEDY 1-69 4 CoV-1, CoV-2 Brouwer et al. (12)
ALC_1780442 ARYDYYDSSGYYLDY 1-69 4
COV2-2270 AITYYYDSSGYWWDD 1-69 4 CoV-1, CoV-2 Zost et al. (38)
ALC_1781971 ASTYYYDSSGYWFDY 1-69 4
COVA2-40 AGRYCSGGRCGWFDP 4-4 5 CoV-2 Brouwer et al. (12)
ALC_1784026 ESRYCSGGSCGWFDP 4-4 5
COV2-2147 ARSTSGSYYYGMDV 3-30-3 6 CoV-1, CoV-2 Zost et al. (38)
CV34 ARSYGGSYYYGMDV 3-30-3 6 CoV-2 Seydoux et al. (40)
ALC_1249094 ARGTRGSYYYGMDV 3-30-3 6
COV2-2006 ARPQSGGYYAPLDY 3-30-3 4 CoV-1, CoV-2 Zost et al. (38)
ALC_1246650 ARPYSGSYYAPLDY 3-30-3 4
S304 ARGDSSGYYYYFDY 3-13 4 CoV-1, CoV-2 CoV-1, CoV-2 Pinto et al. (41)
ALC_1245048 ARGYSSGYYYYFDY 3-13 4
COV2-2027 AIYGYYYYGLDV 3-30 6 CoV-2 Zost et al. (38)
ALC_480504 AVYGYYYYGMDV 3-30 6December 2020 | Volume 1See Supplementary Table 4 for convergent clonotypes with high CDRH3 homology to antibodies in the CoV-AbDab, but not sharing the same IGHV and IGHJ gene usage and allowing
CDRH3 length mismatch. Each row represents a different group of similar sequences. Name: ID of the sequence. Black text represents the convergent clonotypes from this study, and blue
text represents antibodies from CoV-AbDab. CDRH3, CDRH3 amino acid sequence. Green residues represent sequence matches between the convergent clonotype and the CoV-
AbDab sequence, and red residues represent mismatches. IGHV: IGHV gene segment of the sequence. Green text representsmatches between the convergent clonotype and the CoV-AbDab
query sequence, and red text represents mismatches. IGHJ, IGHJ gene segment of the sequence. Green text represents matches between the convergent clonotype and the CoV-AbDab
query sequence, and red text represents mismatches. ND, not determined. Binds/Neutralizes: Experimental confirmation of whether the sequence binds SARS-CoV-1 or SARS-CoV-2.1 | Article 605170
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of diagnostic assays to monitor and predict the progression of
disease in infected patients.
A large number (1,254) of highly convergent clonotypes
unique to COVID-19 were identified. Our approach of
subtracting the convergent clonotypes also observed in healthy
controls, and controls receiving influenza vaccination (22–24),
allowed us to identify convergence specific to the disease
cohort. The unbiased nature of the BCR repertoire analysis
approach means that, while these convergent clonotypes are
likely to include many antibodies to the spike protein and other
parts of the virus they may also include other protective
antibodies, including those to host proteins. Characterization
of the heavy chains we have identified, coupled with matched
light chains to generate functional antibodies will permit analysis
of the binding sites and neutralizing potential of these antibodies.
The report that plasma derived from recently recovered donors
with high neutralizing antibody titers can improve the outcome
of patients with severe disease (50), supports the hypotheses that
intervention with a therapeutic antibody has the potential to be
an effective treatment. A manufactured monoclonal antibody or
combination of antibodies would also provide a simpler, scalable
and safer approach than plasma therapy.
Sequence convergence between our 1,254 convergent
clonotypes with heavy chains from published and patented
SARS-CoV-1 and SARS-CoV-2 antibodies (30) supports
several observations. Firstly, it demonstrates that our approach
of finding a convergent sequence signature is a useful method for
enriching disease-specific antibodies, as we find matches toFrontiers in Immunology | www.frontiersin.org 9known SARS-CoV spike-binding antibodies. Secondly, it shows
that the clonotypes observed in response to SARS-CoV-2 overlap
with those to SARS-CoV-1, presumably explained by the
relatively high homology of the two related viruses (3). Indeed,
here we show that there is an overrepresentation of clonotypes
that correlate with patient clinical symptoms than is expected by
chance, and these BCR sequences are associated with the
dominant IgA1 and IgG1 responses. Finally, it shows that the
convergence extends beyond our UK COVID-19 disease cohort.
Further evidence for convergence extending beyond our
disease cohort came from the comparisons of our 1,254
convergent clonotypes to deep sequencing datasets from China
(28) and the USA (15). The dataset from the USA is also from
BCR sequencing of the peripheral blood of COVID-19 patients,
and here we found matches to 463 of our 1,254 clonotypes. The
dataset from China was from total RNA sequencing of the
bronchoalveolar lavage fluid of SARS-CoV-2 infected patients.
Only 16 unique CDRH3 sequences could be identified in this
whole dataset, but one of them matched a convergent clonotype
in the current study, showing that convergence can be seen both
between different locations, and different sample types. We
believe that the identification of such high BCR sequence
convergence between geographically distinct and independent
datasets could be highly significant and validates the disease
association of the clonotypes, as well as the overall approach.
In summary, our BCR repertoire analysis provides information
on the specific nature of the B cell response to SARS-CoV-2
infection. The information generated has the potential to facilitate
the treatment of COVID-19 by supporting diagnostic approaches to
predict the progression of disease, informing vaccine development
and enabling the development of therapeutic antibody treatments
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